1. Indications and Usage
\nChronic Myeloid Leukemia (CML): Treatment of adult patients with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) .
\nClinical Stages:
\nNewly diagnosed CML in chronic phase.
\nCML in chronic phase or accelerated phase in patients who are resistant or intolerant to prior therapy that included imatinib .
\n2. Dosage and Administration
\nAdministration: Oral administration. Capsules must be swallowed whole with water.
\nFasting Requirement: Must be taken on an empty stomach (no food for at least 2 hours before and at least 1 hour after dosing) to prevent erratic absorption and excessive drug exposure .
\nStandard Dose:
\nResistant\/Intolerant: 400 mg twice daily (approx. every 12 hours) .
\nNewly Diagnosed: 300 mg twice daily .
\nDose Adjustment: Mandatory interruption and dose reduction if QTcF >480 ms or for severe hematologic toxicity (e.g., neutropenia, thrombocytopenia) .
\n3. Mechanism of Action
\nNilotinib is a second-generation BCR-ABL tyrosine kinase inhibitor (TKI).
\nIt binds to the BCR-ABL protein and stabilizes the non-active conformation of the ABL protein kinase site.
\nIt is structurally optimized to have a much higher affinity for the ABL kinase domain than imatinib, allowing it to inhibit many imatinib-resistant BCR-ABL mutations (except T315I) .
\n4. Safety and Warnings
\nQTc Prolongation & Sudden Death: Nilotinib causes QT interval prolongation and has been associated with sudden death. ECG and electrolytes (potassium, magnesium) must be monitored before initiation, 7 days after starting, and periodically thereafter .
\nHepatotoxicity: Severe liver damage may occur. Monitor bilirubin and liver transaminases monthly .
\nPancreatitis: Serum lipase elevation is common; monitor monthly and evaluate for symptoms of pancreatitis .
\nVascular Events: Cases of necrotizing vasculitis and peripheral arterial occlusive disease have been reported .
\n5. Adverse Reactions
\nCommon adverse reactions (incidence \u226510%) include:
\nRash, pruritus, and skin lesions.
\nNausea, diarrhea, vomiting, and constipation.
\nHeadache and fatigue.
\nMusculoskeletal pain and muscle spasms.
\nHematologic abnormalities: Thrombocytopenia, neutropenia, anemia, hyperglycemia .
\n6. Drug Interactions
\nCYP3A4 Substrate:
\nInhibitors: Strong CYP3A4 inhibitors (e.g., ketoconazole, ritonavir, clarithromycin) are contraindicated as they significantly increase Nilotinib exposure.
\nInducers: Strong CYP3A4 inducers (e.g., rifampin, carbamazepine, St. John’s wort) are contraindicated as they reduce efficacy.
\nDrugs that Prolong QT: Concomitant use with other QT-prolonging drugs (e.g., amiodarone, sotalol, haloperidol) should be avoided.
\n7. Pharmaceutical Information
\nChemical Name: 4-Methyl-N-<\/p>\n","protected":false},"excerpt":{"rendered":"
Brand Name:\u8fbe\u5e0c\u7eb3\u00ae (Tasigna\u00ae)<\/p>\n
Generic Name:Nilotinib<\/p>\n
Strength:200 mg per capsule, 112 capsules per box<\/p>\n
Manufacturer: Novartis Pharma Stein AG (Switzerland)<\/p>\n
Marketing Authorization Holder:Novartis Pharma AG; Domestic marketing: Novartis Oncology (China) Co., Ltd.<\/p>\n
Approval Date in China: November 2009 (original marketing approval; updated supplementary approval issued 2017)<\/p>\n
Registration Number:\u56fd\u836f\u51c6\u5b57HJ20171152<\/p>\n
Storage:Sealed and protected from light, stored below 30\u00b0C, keep away from children<\/p>\n
Price&Cost:Contact Us now for the best price of Nilotinib\uff08Tasigna\uff09<\/p>\n","protected":false},"featured_media":2839,"comment_status":"open","ping_status":"closed","template":"","meta":[],"product_brand":[80],"product_cat":[26],"product_tag":[],"class_list":["post-2838","product","type-product","status-publish","has-post-thumbnail","product_brand-novartis","product_cat-capsules","first","instock","shipping-taxable","product-type-simple"],"yoast_head":"\n